Successful Treatment of Primary Cardiac Lymphoma With Monoclonal CD20 Antibody (Rituximab)

Yukinori Nakagawa; Uichi Ikeda; Masahiro Hirose; Satoshi Ubukata; Taka-aki Katsuki; Yuichiro Kaminishi; Tsutomu Saito; Mitsugu Hironaka; Tohru Izumi; Kazuyuki Shimada

doi:10.1253/circj.68.172

Case Report

Successful Treatment of Primary Cardiac Lymphoma With Monoclonal CD20 Antibody (Rituximab)

Yukinori Nakagawa, Uichi Ikeda, Masahiro Hirose, Satoshi Ubukata, Taka-aki Katsuki, Yuichiro Kaminishi, Tsutomu Saito, Mitsugu Hironaka, Tohru Izumi, Kazuyuki Shimada

Author information

Yukinori Nakagawa
Divisions of Cardiovascular Medicine, Jichi Medical School
Uichi Ikeda
Divisions of Cardiovascular Medicine, Jichi Medical School
Masahiro Hirose
Divisions of Cardiovascular Medicine, Jichi Medical School
Satoshi Ubukata
Divisions of Cardiovascular Medicine, Jichi Medical School
Taka-aki Katsuki
Divisions of Cardiovascular Medicine, Jichi Medical School
Yuichiro Kaminishi
Divisions of Cardiovascular Surgery, Jichi Medical School
Tsutomu Saito
Divisions of Cardiovascular Surgery, Jichi Medical School
Mitsugu Hironaka
Divisions of Pathology, Jichi Medical School
Tohru Izumi
Divisions of Hematology, Jichi Medical School
Kazuyuki Shimada
Divisions of Cardiovascular Medicine, Jichi Medical School

Keywords: Antibody, B cells, Cardiac tumor, Lymphoma

JOURNAL FREE ACCESS

2004 Volume 68 Issue 2 Pages 172-173

DOI https://doi.org/10.1253/circj.68.172

Details

Abstract

Primary cardiac malignant lymphoma is extremely rare and almost all patients die within weeks. Monoclonal CD20 antibody (rituximab) was administered to a patient with primary cardiac B-cell non-Hodgkin's lymphoma expressing a CD20 molecule. The results suggest that rituximab may be a safe and effective new therapy for primary cardiac B-cell lymphoma. (Circ J 2004; 68: 172 - 173)

Corresponding author

Register with J-STAGE for free!